References
- Aguilar-Markulis NV, Beckley S, Priore R, Mettlin C. Auditory toxicity effects of long-term cis-dichlorodiam-mine platinum II therapy in genito urinary cancer patients. J Surg Oncol 1981;16:111–23.
- Castello MA, Clerico A, Deb G, Dominici C, Fidani P, Donfrancesco A. High dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors. Am J Pediatr Hematol Oncol 1990;12:297–300.
- Coupland SG, Ponton CW, Eggermont JJ, Bowen TJ, Grant RM. Assessment of cisplatin-induced ototoxicity using derived-band ABRs. Int J Pediatr Otorhinolaryngol 1991;22:237–48.
- Delb W, Feilen S, Koch A, Federspil P. Experimental investigations on the ototoxicity of cisplatin and carbo-platin. Laryngo-Rhino-Otol 1993;72/1:24–7.
- Fausti SA, Frey HR, Henry JA, Olson DJ, Schaffer HI. Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses. J Am Acad Audiol 1992;3:397–404.
- Gratton MA. The interaction of cisplatin and noise on the peripheral auditory system. Hear Res 1990;50:211–224.
- Helson L, Okonkwo E, Anton L, Cvitkovic E. Cis-platinum ototoxicity. Clin Toxicol 1978;13:469–79.
- Jerger J. Diagnostic use of impedance measures. In: Handbook of clinical impedance audiometry. Dobbs Ferry, N.Y.: Morgan Press, 1975;149–74.
- Jewett DL, Williston JS. Auditory evoked far fields averaged from the scalp of humans. Brain 1971;94: 681–96.
- Kennedy IC, Fitzharris BM, Colls BM, Atkinson CH. Carboplatin is ototoxic. Cancer Chemother Pharmacol 1990;26:232–4.
- Kingston JE, Abramovich S, Billings RJ, Malpas JS, Fuller AP. Assessment of the effect of chemotherapy and radiotherapy on the auditory function of children with cancer. Clin Otolaryngol 1986;11:403–9.
- Lau SK, Wei WI, Sham JS, Choy DTK, Hui Y. Early changes of auditory brain stem evoked response after radiotherapy for nasopharyngeal carcinoma. A prospec-tive study. J Laryngol Otol 1992;106:887–92.
- Laurell G, Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 1990;100:724–34.
- Maiese K, Walker RW, Gargan R, Victor JD. Intra-arterial cisplatin-associated optic and otic toxicity. Arch Neurol 1992;49:83–6.
- Metz O. The acoustic impedance measured on normal and pathological ears. Acta Otolaryngol (Stockh) 1946; (Suppl 63):397–405.
- Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55.
- Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersal HN. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 1982;66:19–23.
- Rybak LP. Cisplatinum associated hearing loss. J Laryngol Otol 1981;95:745–7.
- Schweitzer VG. Cisplatin-induced ototoxicity: effect of pigmentation and inhibitory agents. Laryngoscope 1993; 103 (Suppl 59):1–52.
- van der Hulst RJAM, Dreschler WA, Urbanus NAM. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 1988;97:133–7.
- Vermorken JB, Kapteijn TS, Hart AAM, Pinedo HM. Ototoxicity of cis-diammine dichloroplatinum (II). Influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983;19:53–8.
- Weatherly RA, Owen JJ, Catlin Fl, Mahoney DH. Cisplatinum ototoxicity in children. Laryngoscope 1991; 101:917–24.
- Wright CG, Schaefer SD. Inner ear histopathology in patients treated with cis-platinum. Laryngoscope 1982; 92:1408–13.